Biotechnology

With a key webinar ahead, Arrowhead Pharma is showcasing a trio of gene-silencing drugs. Can its TRiM™ platform upend a multi-billion dollar cardiometabolic market?

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

With enhanced GMP cell banking suites, Minaris integrates manufacturing and testing in Philadelphia, aiming to accelerate development in the booming CGT market.

A new spray-dried plasma could end reliance on freezers, transforming trauma care from the battlefield to rural ERs. But can Velico navigate the path to market?

RedHill Biopharma's new financing provides crucial cash, but the real story is in the warrants and the hunt for a strategic acquisition. A deep dive.

With a fresh $50M, Enhanced Group is selling a future of medically-guided peak performance. But can its controversial Games and peptide platform survive regulatory scrutiny?

A new patent gives CervoMed a long runway for its dementia drug, but can this IP victory secure the massive funding needed to cross the finish line?

Asimov's AI-driven synthetic biology platform partners with McGill's Goodman Cancer Institute, aiming to break the manufacturing bottleneck for complex drugs.

Memo Therapeutics' Potravitug shows promise in a Phase II trial, offering the first real weapon against a common virus that threatens kidney transplants.

Merck secures a pivotal FDA approval for its CAPVAXIVE vaccine, offering new hope for at-risk youth and challenging rivals in the high-stakes pneumococcal market.

As CFO Dave Denton departs for the consumer goods sector, Pfizer taps a 20-year veteran for the interim role, signaling continuity amid a crucial post-acquisition phase.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

A half-million dollar grant is just the start. A new public-private alliance is mobilizing to fight blast-induced brain injuries. Here's the story behind the numbers.

Early trial data for a novel antibody-drug conjugate shows a 32% response rate in a hard-to-treat patient group, signaling a potential new front in precision oncology.

German biotech Mallia Aesthetics reports impressive results for its hormone-free hair serum, but the real story lies in its resilient, science-first strategy.

After three decades, a new class of therapy for a rare liver disease lands in Singapore, rewriting the rules of care by targeting patient suffering, not just lab results.

Iceland's Alvotech secured a crucial capital infusion. It's a high-stakes play to survive financial pressures and compete in the next wave of affordable medicine.

A new report projects the wellness market will hit $12.9T by 2031. This isn't just about yoga mats; it's a tech-fueled, Asia-led economic realignment.

As Oncoinvent accelerates its Phase 2 trial, a novel alpha-emitter therapy shows promise against a deadly cancer, signaling progress in radiopharmaceuticals.